Bronchopulmonary Dysplasia (BPD)
Conditions
Interventions
Observation Group 1:Calf Pulmonary Surfactant 100mg/kg was intratracheal dripping, and budesonide suspension 400ug was atomized and inhaled at Q12h until extubation
Observation Group 2:Calf Pulmonary Surfactant 100mg/kg was intratracheal dripping, and budesonide suspension 200ug was atomized and inhaled at Q12h until extubation
Observation Group 3:Calf Pulmonary Surfactant 100mg/kg and budesonide suspension 250 ug/kg was intratracheal dripping, and budesonide suspension 200ug was atomized and inhaled at Q12h until extubation
Control Group:Calf Pulmonary Surfactant 100mg/kg was intratracheal dripping
Sponsors
Maternal and Child Health Hospital of Hubei Province
Eligibility
Sex/Gender
All
Age
No minimum to 2 Years
Inclusion criteria
Inclusion criteria: 1. The gestational age <30 weeks or birth weight <1500 g; 2. The diagnosis of respiratory distress syndrome (RDS) after birth requires treatment with surfactant (Calf Pulmonary Surfactant); 3. Clinical dyspnea occurred within 12 hours after birth and mechanical ventilation was required; 4. Obtain informed consent from the parent or guardian of the neonate.
Exclusion criteria
Exclusion criteria: Severe congenital deformity or severe congenital heart and lung disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of BPD;Physical development index and intellectual development index;Inflammatory factors in bronchoalveolar lavage fluid (IL-1, IL-6, IL-8, TNF-alpha, NF-kB); | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of complications in premature infants; | — |
Countries
China
Contacts
Public ContactXia Shiwen
Maternal and Child Health Hospital of Hubei Province
Outcome results
None listed